Navigation Links
Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis

VICTORIA, BC, Canada and BASEL, Switzerland, June 27 /CNW/ - Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) and Roche today released preliminary results for a clinical trial comparing CellCept (oral mycophenolate mofetil, MMF) to intravenous cyclophosphamide (IVC), which is the current standard of care, for inducing treatment response in the induction phase of patients suffering from lupus nephritis.

Although response rates were similar in both arms, the trial did not meet its primary objective of demonstrating that MMF was superior to IVC in inducing treatment response in this disease. The results relate to the induction phase of this study, which was designed to measure treatment response in patients after 24 weeks of induction therapy with 185 patients in the MMF arm and 185 in the IVC arm. The results indicate similar treatment responses with 56.2% in the MMF arm and 53% in the IVC arm were observed. Additional analyses are ongoing to determine the potential for a regulatory submission and Aspreva plans to present the final results at an appropriate scientific forum.

Based on preliminary analysis, it appears that, in general, the adverse events experienced by patients in both arms of the study are consistent with those observed in lupus nephritis patients receiving immunosuppressive therapy. Overall incidence of adverse events was comparable in both treatment arms. Aspreva will host a conference call today at 9:30 a.m. ET (6:30 a.m. PT) to discuss these preliminary results.

About Lupus Nephritis

Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disease that causes the body to attack its own tissues and joints. Lupus nephritis, considered life-threatening, but rare, is the most serious manifestation of SLE. If left untreated, it can lead to kidney failure, need of dialysis, and potentially death. It is a complicated disease as patients typic
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:10/22/2014)... -- A new report by Allied Market ... End user, Application and Geography) - Size, Share, Global ... Segmentation and Forecast, 2013 - 2020", considers commercial aspects ... trends tracked, it is anticipated that the market is ... registering a CAGR of 6.2% from 2014 to 2020. ...
(Date:10/22/2014)... Oct. 21, 2014   BioNano Genomics , ... genomics research centers to purchase an Irys™ System ... National Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) ... Irys, obtaining a comprehensive view of a genome ... (NGS) does not deliver the scalability or reliability ...
(Date:10/22/2014)...   Surefire Medical , Inc., the developer of ... targeted delivery of embolization agents in minimally invasive direct-to-tumor ... John R. Daniels , MD of the University of ... Steven C. Katz , MD of the Roger ... Board (SAB).    "The role of the ...
Breaking Medicine Technology:Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
... Calif., Oct. 6 PRO-DEX, INC. (Nasdaq: PDEX ... as Chief Financial Officer, effective October 6, 2010.  Mr. Hurwitz ... "Hal comes to Pro-Dex with a broad financial background ... with Coopers & Lybrand LLP, now part of PricewaterhouseCoopers LLP, ...
... DiFUSION Technologies Inc., a medical device company focused ... CleanFUZE™ anti-microbial technology for orthopedic implants, announced today ... of posterior interbody devices indicated for intervertebral body ... SI, in skeletally mature patients who have had ...
Cached Medicine Technology:Pro-Dex, Inc. Appoints Harold A. Hurwitz as Chief Financial Officer 2DiFUSION Technologies Receives 510(k) Clearance of Xiphos™ Interbody Implants for Spinal Fusion 2
(Date:10/22/2014)... On October 22, CBS will air an ... both fictional and real. The Charles E Holman ... to advocacy and philanthropy in the battle against Morgellons ... to impart truth and clarity about this misunderstood and ... misconceptions about Morgellons Disease (MD) and most ...
(Date:10/22/2014)... 22, 2014 Isabel Healthcare ... Health Professions (ASAHP) Conference on October 22-24 in Las ... participate in a panel discussion on Technology in Health ... Healthcare provides a diagnostic decision support tool and clinical ... skills of students and clinical learners. The Isabel tools ...
(Date:10/22/2014)... Amy Norton HealthDay Reporter ... remain riveted on the three Ebola cases in Dallas. But, ... health threat to Americans. President Barack Obama on Friday ... the virus, which has infected two Dallas nurses who cared ... at Texas Health Presbyterian Hospital. But the U.S. cases ...
(Date:10/22/2014)... Shriners Hospitals for Children® and UK ... current location of Shriners Hospitals for Children - Lexington ... the University of Kentucky Albert B. Chandler Hospital. The ... owned and operated by Shriners Hospitals for Children, and ... and their families well into the future. , “The ...
(Date:10/22/2014)... California (PRWEB) October 22, 2014 Hay House ... Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written ... of Yoga & Recovery. This book is meant to ... in a life of recovery. , Recovery 2.0 is ... 12 Steps; Recovery 2.0 is a guide for what comes ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3
... 2008 Vaccinating infants and toddlers is an almost universal ... a regular part of medical care for senior citizens and ... August 2008 issue of the American Journal of Preventive ... in getting vaccines to the adolescent population. , In response ...
... 7 Most of us opt for bottled,water as ... while on the go. Now Filters Fast,( http://www.filtersfast.com ), ... and eco-friendly alternative with its new reusable,filtered water bottles. ... or,water fountain, and the bottles will filter the water ...
... Haemonetics,Corporation (NYSE: HAE ) will announce its Q1FY09 earnings on August ... Conference Call Dial-In Information (888) 802-8577 (US ... #: 54880152 This call will be replayed through August 15, ... (800) 642-1687 (US & Canada) (706) 645-9291 ...
... expected to grow over ... 150% from 2007 second quarter, ... manufacturer and marketer of state-of-the-art cardiac,surgery products and services, today ... 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ), The Company currently ...
... people are becoming more positive towards surrogate mothers, ... negative, a scientist will tell the 24th annual ... and Embryology tomorrow (Monday 7 July). Professor Olga ... Middlesex University, Hendon, London, UK, will say that ...
... University of Washington have reported a significant reduction of ... syrup xylitol, a naturally occurring non-cavity-causing sweetener. Their,results were ... International Association for Dental Research. , In a recent ... children 6 to 15 months old were given oral ...
Cached Medicine News:Health News:National Vaccine Advisory Committee recommends increased adolescent immunization 2Health News:National Vaccine Advisory Committee recommends increased adolescent immunization 3Health News:Filters Fast Advocates Use of Filtered Water Bottles for Environmental and Personal Health 2Health News:ATS Medical Expects Second Quarter Revenue of $16.7 to $16.9 Million 2Health News:ATS Medical Expects Second Quarter Revenue of $16.7 to $16.9 Million 3Health News:Surrogacy still stigmatized, though attitudes changing among younger women 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: